Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Atrium Therapeutics (Nasdaq: RNA) granted equity inducement awards on August 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The package includes non-qualified options for 11,000 shares at an exercise price of $13.48 and 5,500 restricted stock units, with multi-year time-based vesting, approved by the board’s independent Human Capital Management Committee under Nasdaq Listing Rule 5635(c)(4).

Market Context

Current risk data categorizes RNA's short positioning as moderate, while insider data reports no rec...

Analysis

Current risk data categorizes RNA's short positioning as moderate, while insider data reports no recent activity. The inducement awards add compensation context; continued-service vesting remains a material term in the disclosure.

Key Figures

Grant Date: August 20, 2026 Option Shares: 11,000 shares Exercise Price: $13.48 per share +4 more

7 metrics

Grant Date August 20, 2026 Inducement awards

Option Shares 11,000 shares Non-qualified stock options

Exercise Price $13.48 per share Closing price on the grant date

Initial Option Vesting 25% Vests on the first anniversary of the grant date

Remaining Option Vesting 36 installments Substantially equal monthly installments

RSU Shares 5,500 shares Restricted stock units

Remaining RSU Vesting 3 installments Substantially equal annual installments

Historical Context

5 past events · Latest: Aug 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	Q2 earnings report	Positive	+4.1%	Reported Q2 results, FDA IND clearance, BMS milestone, and projected funding through mid-2028
Aug 13	BMS milestone payment	Positive	+1.3%	Earned a second $15 million milestone payment under the Bristol Myers Squibb collaboration
Jul 20	Inducement grants	Neutral	+4.5%	Granted options and RSUs to one newly hired non-executive employee
Jul 14	FDA IND clearance	Positive	+0.0%	FDA clearance enabled the Corventis Phase 1/2 trial for PRKAG2 syndrome
Jun 23	Inducement grants	Neutral	+0.2%	Granted options and RSUs to eight newly hired non-executive employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Inducement-grant announcements were followed by positive 24-hour reactions of 4.51% and 0.16%, while the FDA-clearance event had a 0.00% reaction, indicating varied historical responses.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"received, in the aggregate, non-qualified stock options to purchase 11,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units for an aggregate of 5,500 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

The employee received, in the aggregate, non-qualified stock options to purchase 11,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $13.48 per share, the closing price of the Company's common stock as reported by Nasdaq on the grant date, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remainder of which will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 5,500 shares of the Company's common stock, 25% of which will vest on the first anniversary of the grant date, and the remainder of which will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date (collectively, the "Awards").

All of the above-described Awards were granted pursuant to the 2026 Inducement Plan. The Awards were approved by the Human Capital Management Committee of the Company's Board of Directors, which is comprised solely of independent directors, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.

For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302856886.html

SOURCE Atrium Therapeutics

FAQ

What did Atrium Therapeutics (NASDAQ: RNA) announce on August 20, 2026?

Atrium Therapeutics announced equity inducement grants for a newly hired non-executive employee on August 20, 2026. According to the company, the awards were granted under its 2026 Employment Inducement Incentive Award Plan as a material inducement to join the company.

How many stock options and RSUs were granted in Atrium Therapeutics (RNA) inducement awards?

Atrium Therapeutics granted non-qualified stock options for 11,000 shares and 5,500 restricted stock units to one new employee. According to the company, these equity awards form part of the employee’s compensation package and were issued under the 2026 Employment Inducement Incentive Award Plan.

What is the exercise price and vesting schedule of the Atrium Therapeutics (RNA) inducement stock options?

The inducement stock options have an exercise price of $13.48 per share, the closing price on the grant date. According to the company, 25% vest after one year, and the remaining 75% vest in 36 substantially equal monthly installments, subject to continued service.

How do the restricted stock units from Atrium Therapeutics (RNA) inducement grant vest?

The 5,500 restricted stock units vest 25% on the first anniversary of the grant date. According to the company, the remaining 75% vest in three substantially equal annual installments, contingent on the employee’s continued service through each vesting date.

Under which plan and Nasdaq rule were Atrium Therapeutics (RNA) inducement awards granted?

The awards were granted under Atrium Therapeutics’ 2026 Employment Inducement Incentive Award Plan. According to the company, the Human Capital Management Committee of the board approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).